NCT04144569View on ClinicalTrials.gov

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

PHASE2RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

December 30, 2024

Study Completion Date

December 31, 2024

Conditions

HER2 Insertion Mutation Positive Advanced NSCLC

Interventions

DRUG

PD-1 Combined With Pyrotinib

PD-1 Combined With Pyrotinib

Trial Locations (1)

410013

RECRUITING

Hunan Provincal Tumor Hospital, Changsha

All Listed Sponsors

lead

Yongchang Zhang

OTHER